markets · · proactiveinvestors.com
Cellbxhealth signs new statement of work with US pharma company
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), which develops technology to collect tumour cells from blood, has signed a new statement of work worth around $65,000 with an existing US pharmaceutical customer. The agreement covers processing around 100 patient samples using its Parsortix platform to isolate and collect circulating tumour cells for molecular analysis, including mRNA analysis.
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), which develops technology to collect tumour cells from blood, has signed a new statement of work worth around $65,000 with an existing US pharmaceutical customer. The agreement covers processing around 100 patient samples using its Parsortix platform to isolate and collect circulating tumour cells for molecular analysis, including mRNA analysis.
- #ANPCF